Plasma Cell Myeloma Clinical Trial
Official title:
The Role of the Comprehensive Geriatric Assessment in Elderly Patients With Multiple Myeloma: A Single Center Prospective Study
Verified date | December 2023 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study evaluates the association between a comprehensive geriatric assessment and laboratory biomarkers with the side effects of chemotherapy in older patients with multiple myeloma (MM). The comprehensive geriatric assessment is a tool that can help to determine how fit a patient is. It is composed of a series of questions and tests designed for older people to evaluate their physical function, mental status, mental health, nutritional status, social support, level of social activity, and the presence of other medical problems. In addition to geriatric assessment domains, laboratory biomarkers may provide information on physiologic dysfunction as a measure for evaluation of frailty in the cancer setting. This study will help researchers in the future by predicting which patients will have more side effects with chemotherapy based on their comprehensive geriatric assessment and laboratory biomarkers, which will allow adjustments to treatment in older adult patients with MM.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: - Age >= 65 years - Diagnosis of MM based on International Myeloma Working Group (IMWG) diagnostic criteria - Newly diagnosed or have received 1 prior line of treatment - Planned to start a new treatment for MM within 30 days - Transplant eligible or ineligible - Fluent in English (all assessment tools are in English) - Able to provide written informed consent Exclusion Criteria: - Received > 1 prior line of treatment - Patients included in an interventional therapeutic trial - Not able to give informed consent - Severe mental or cognitive disorder precluding geriatric assessment |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of treatment-related adverse events | Will graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The maximum observed grade per adverse event and capture grade >= 3 toxicities. | Up to 4 months | |
Secondary | Chemotherapy toxicity | Will be analyzed longitudinally using toxicity over time analysis which measures adverse events over time, providing information on timing and evolution of symptoms during treatment. | Up to 4 months | |
Secondary | Patient reported outcome (PRO) questionnaire | Will be assessed at the end of each treatment cycle (prior to each new cycle) at scheduled visits for a total of 4 months or until treatment discontinuation whichever comes first using the PRO Measurement Information System Global Health which is a 10-item questionnaire that assesses a patient's global heath. All questions have a five-point Likert-type scale, except for the rating of pain question which has a 10-point scale. Subscale scores can be generated for Global Physical Health and Global Mental for each patient. | Up to 4 months | |
Secondary | Patient reported outcome (PRO-CTCAE) questionnaire | Select PRO-CTCAE symptomatic adverse event items to assess the presence, severity and interference of symptoms experienced by patients. | Up to 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Completed |
NCT02513186 -
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Completed |
NCT02880228 -
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT04782687 -
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
|
Phase 2 | |
Completed |
NCT02514668 -
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma
|
Phase 1 | |
Active, not recruiting |
NCT03417284 -
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05142371 -
Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors
|
N/A | |
Terminated |
NCT03272633 -
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
|
Early Phase 1 | |
Recruiting |
NCT05031897 -
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
|
Phase 2 | |
Active, not recruiting |
NCT03275285 -
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
|
Phase 3 | |
Completed |
NCT04100044 -
Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma
|
N/A | |
Active, not recruiting |
NCT00075478 -
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
Phase 3 | |
Recruiting |
NCT05561387 -
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
|
Phase 3 | |
Completed |
NCT03317899 -
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT05511428 -
Home Based Daratumumab Administration for Patients With Multiple Myeloma
|
Early Phase 1 | |
Completed |
NCT01919619 -
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
|
Phase 2 | |
Terminated |
NCT02353572 -
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04537871 -
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
|
||
Active, not recruiting |
NCT00719888 -
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
|
Phase 2 |